🏛️ Verified NIH Record • Updated 2026-07-01

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (16 items).

Location: The University of Arizona Cancer Center — Tucson, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Previous systemic therapy for locally advanced or metastatic disease is not allowed.
  • Have a history of or have current hepatic encephalopathy of any grade, or ascites of Grade \>1, or cirrhosis with Child-Pugh Stage B or higher.
  • Have ongoing or recent (≤6 months) hepatorenal syndrome.
  • Have had a major surgical procedure or significant traumatic injury including nonhealing wound, peptic ulcer, or bone fracture ≤28 days prior to randomization.
  • Anticipate having a major surgical procedure during the course of the study.
  • Has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
  • Within 6 months prior to randomization, have had any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
  • Have an uncontrolled arterial hypertension with systolic blood pressure ≥150 or diastolic blood pressure ≥90 millimeters of mercury (mm Hg) despite standard medical management.
  • Have a previous malignancy within 5 years of study entry or a concurrent malignancy.
  • Have a history of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
  • Have a known allergy or hypersensitivity reaction to any of the treatment components.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (82 Sites)

  • The University of Arizona Cancer Center — Tucson, Arizona
  • UCSF Medical Center at Mission Bay — San Francisco, California
  • Georgetown University Medical Center — Washington D.C., District of Columbia
  • University of Florida School of Medicine — Gainesville, Florida
  • Karmanos Cancer Institute — Detroit, Michigan
  • Washington University Medical School — City of Saint Peters, Missouri
  • Washington University Medical School — Creve Coeur, Missouri
  • Washington University Medical School — St Louis, Missouri
  • Washington University Medical School — St Louis, Missouri
  • Thomas Jefferson University — Philadelphia, Pennsylvania
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • Florida Cancer Specialists — Nashville, Tennessee
  • Tennessee Oncology PLLC — Nashville, Tennessee
  • Alexander Fleming — CABA, BS
  • Hospital de Gastroenterologia Udaondo — Capital Federal, Buenos Aires
  • Fundacion Ars Medica — San Salvador de Jujuy, Jujuy Province
  • Clinica Viedma — Viedma, Río Negro Province
  • Centro Medico San Roque — San Miguel de Tucumán, Tucumán Province
  • Fundacion Favaloro — Ciudad de Buenos Aires,
  • Fundación CORI para la Investigación y Prevención del Cáncer — La Rioja,
  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan — San Juan,
  • Calvary Mater Newcastle — Waratah, New South Wales
  • Royal Adelaide Hospital — Adelaide, South Australia
  • Austin Health — Heidelberg, Victoria
  • Landesklinikum Wr. Neustadt — Wiener Neustadt, Lower Austria

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗